115 related articles for article (PubMed ID: 26014941)
1. Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs).
Schotte L; Thys B; Strauss M; Filman DJ; Rombaut B; Hogle JM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4695-706. PubMed ID: 26014941
[TBL] [Abstract][Full Text] [Related]
2. Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site.
Strauss M; Schotte L; Thys B; Filman DJ; Hogle JM
J Virol; 2016 Jan; 90(7):3496-505. PubMed ID: 26764003
[TBL] [Abstract][Full Text] [Related]
3. In vitro antiviral activity of single domain antibody fragments against poliovirus.
Thys B; Schotte L; Muyldermans S; Wernery U; Hassanzadeh-Ghassabeh G; Rombaut B
Antiviral Res; 2010 Aug; 87(2):257-64. PubMed ID: 20566349
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity.
Schotte L; Strauss M; Thys B; Halewyck H; Filman DJ; Bostina M; Hogle JM; Rombaut B
J Virol; 2014 Apr; 88(8):4403-13. PubMed ID: 24501405
[TBL] [Abstract][Full Text] [Related]
5. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
6. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
[TBL] [Abstract][Full Text] [Related]
7. Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.
Puligedda RD; Kouiavskaia D; Adekar SP; Sharma R; Devi Kattala C; Rezapkin G; Bidzhieva B; Dessain SK; Chumakov K
Antiviral Res; 2014 Aug; 108():36-43. PubMed ID: 24824031
[TBL] [Abstract][Full Text] [Related]
8. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.
Mosser AG; Sgro JY; Rueckert RR
J Virol; 1994 Dec; 68(12):8193-201. PubMed ID: 7966611
[TBL] [Abstract][Full Text] [Related]
9. Revertants of poliovirus escape mutants: new insights into antigenic structures.
Ketterlinus R; Wiegers K; Dernick R
Virology; 1993 Feb; 192(2):525-33. PubMed ID: 8380664
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation.
Harmsen MM; van Solt CB; Fijten HP
Appl Microbiol Biotechnol; 2009 Oct; 84(6):1087-94. PubMed ID: 19455325
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
Salvati AL; De Dominicis A; Tait S; Canitano A; Lahm A; Fiore L
Antimicrob Agents Chemother; 2004 Jun; 48(6):2233-43. PubMed ID: 15155227
[TBL] [Abstract][Full Text] [Related]
12. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
[TBL] [Abstract][Full Text] [Related]
13. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.
Chen Z; Chumakov K; Dragunsky E; Kouiavskaia D; Makiya M; Neverov A; Rezapkin G; Sebrell A; Purcell R
J Virol; 2011 May; 85(9):4354-62. PubMed ID: 21345966
[TBL] [Abstract][Full Text] [Related]
14. Selection and identification of single-domain antibody fragment against capsid protein of porcine circovirus type 2 (PCV2) from C. bactrianus.
Yang S; Shang Y; Yin S; Tian H; Chen Y; Sun S; Jin Y; Liu X
Vet Immunol Immunopathol; 2014 Jul; 160(1-2):12-9. PubMed ID: 24736187
[TBL] [Abstract][Full Text] [Related]
15. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.
Liu HM; Roberts JA; Moore D; Anderson B; Pallansch MA; Pevear DC; Collett MS; Oberste MS
Antimicrob Agents Chemother; 2012 Nov; 56(11):5568-74. PubMed ID: 22890765
[TBL] [Abstract][Full Text] [Related]
16. A simple quantitative affinity capturing assay of poliovirus antigens and subviral particles by single-domain antibodies using magnetic beads.
Thys B; Saerens D; Schotte L; De Bleeser G; Muyldermans S; Hassanzadeh-Ghassabeh G; Rombaut B
J Virol Methods; 2011 May; 173(2):300-5. PubMed ID: 21371506
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of Junín virus by single domain antibodies targeted against the nucleoprotein.
Linero F; Sepúlveda C; Christopoulou I; Hulpiau P; Scolaro L; Saelens X
Sci Rep; 2018 Jul; 8(1):11451. PubMed ID: 30061671
[TBL] [Abstract][Full Text] [Related]
18. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris.
Rahbarizadeh F; Rasaee MJ; Forouzandeh M; Allameh AA
Mol Immunol; 2006 Feb; 43(5):426-35. PubMed ID: 16337485
[TBL] [Abstract][Full Text] [Related]
19. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds.
Rhoden E; Liu HM; Wang-Chern SW; Oberste MS
Antiviral Res; 2013 May; 98(2):186-91. PubMed ID: 23499651
[TBL] [Abstract][Full Text] [Related]
20. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
